WASHINGTON, DC — The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.“The Biosimilars Council and AAM applauds unanimous Senate passage of the Cornyn-Blumenthal legislation,” said Craig Burton, executive director of the biosimilars council. “Patent thickets are used by brand pharmaceutical companies to maintain high prices and deny patients access to lower-cost medicines. This legislation is a great step in curbing these abuses and will help increase competition and access for biosimilars. We encourage the House to take up this legislation and for Congress to continue working to help lower costs for patients.”
Biosimilars Council applauds patent abuse act
The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.
Related
APhA voices concern over hepatitis B recommendation change
This reversal rolls back a highly effective, evidence-based public health measure that has been in place since 1991.
Senate finance leaders introduce bipartisan PBM Reform, NACDS hails move and calls for swift passage
Legislation aims to curtail harmful PBM middlemen tactics that inflate drug costs and force pharmacies to close.
NCPA urges Congress to pass Crapo-Wyden PBM Reforms
Wide bipartisan support means no more excuses, says NCPA.
Walgreens expands micro-fulfillment network with new facility in West Jordan, Utah
The micro-fulfillment center (MFC) will support nearly 96 stores across the region.
Latest
RXBAR expands beyond the bar with new Protein Energy Bites
A craveable, bite-sized innovation delivering protein, fiber, and fueling energy — now available nationwide.
APhA voices concern over hepatitis B recommendation change
This reversal rolls back a highly effective, evidence-based public health measure that has been in place since 1991.
Retailers should matter to legislators
Two issues in particular — credit card “swipe fees” and organized retail crime (ORC) — illustrate how slow congressional action and regulatory inertia are costing businesses and consumers alike.
Health care’s cost is unsustainable
Businesses’ cost concerns and the profitability struggles of providers point to the urgent need for reform.